Study identifier:D7680C00001
ClinicalTrials.gov identifier:NCT06192004
EudraCT identifier:N/A
CTIS identifier:N/A
An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD
Non-small Cell Lung Cancer
N/A
No
-
All
600
Observational
18 Years - n/a
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
-
This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution. Patients initiating treatment for non-small cell lung cancer (NSCLC) will be prospectively followed to characterize risk factors, signs, and symptoms leading to onset, diagnosis, and treatment of pneumonitis/ILD should it occur.
This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution. Data will be collected prospectively from study sites using eCRFs and remotely from patients using a digital health tool.
Location
Status
Location
Troy, Michigan, United States, 48098
Status
Recruiting
Location
Los Angeles, California, United States, 90027
Status
Recruiting
Location
Mickleton, New Jersey, United States, 08056
Status
Recruiting
Location
Skokie, Illinois, United States, 60076
Status
Recruiting
Location
Massillon, Ohio, United States, 44646
Status
Recruiting
Location
Westbury, New York, United States, 11590
Status
Recruiting
Location
Canton, Ohio, United States, 44710
Status
Recruiting
Location
Canton, Ohio, United States, 44708
Status
Recruiting
Arms | Assigned Interventions |
---|---|
Prospective Cohort NSCLC patients initiating an approved treatment with risk of pneumonitis/ILD. | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.